Hospital-Community-Family-Care Management Platform for Chronic Heart Failure

NCT ID: NCT02029287

Last Updated: 2019-07-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 1000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-12-31
• Study Completion Date: 2020-12-31

Brief Summary

The purpose of this study is to determine whether the Hospital-Community-Family-Care Management Platform for Chronic Heart Failure reduces the mortality, readmission rates and costs of the subjects with CHF.

Detailed Description

(1) Indication: Chronic Heart Failure. (2) Objectives: Primary objective is to evaluate the efficacy of the Hospital-Community-Family-Care Management Platform online compared with the regular clinic follow up in subjects with CHF (I-IV class by NYHA, of which class IV without strict bed rest).Secondary objectives is to assess the safety of the Management Platform online in subjects with CHF. (3) Study design: Prospective, randomized, controlled study with two follow up management groups: 1) the Hospital-Community-Family-Care Management Follow up Online; 2) the regular monthly clinic follow up. Study population: Totally 1000 male and female subjects with CHF (I-IV functional class according to NYHA classification). (4) Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing. (5) Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry. (6) Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources. (7) Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. (8) Duration of follow up: The total follow-up time shall be at least 12 months. (9) Safety Assessment: Safety of the study will be evaluated by the following assessments: 1) Subject and object examinations (during the follow up period and extending up to 2 week after the end of the study) consisting of a subject interview (including direct questioning about adverse events), physical examination, assessment of body weight, Electrocardiogram (ECG) and echocardiogram (UCG), Left ventricular ejection fraction (LVEF), assessed by echocardiography, The N-terminal prohormone of brain natriuretic peptide (NT-proBNP), a peptide hormone whose plasma concentration is inversely related to the severity of HF, NYHA functional status, assessed by subject interview, 6-minute walk distance (6MWD), Quality of life (QoL), assessed by the Minnesota Living with Heart Failure questionnaire (MLHFQ), a validated questionnaire assessing QoL in subjects with heart failure. 2) Evaluation of clinically relevant safety laboratory parameters, such as complete blood count, serum creatinine, electrolytes, and liver enzymes. Any Adverse Events (AE) or Serious Adverse Events (SAE) and its potential causal relationship with the study will be recorded and evaluated.

Conditions

Chronic Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Subjects with CHF follow-up

Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of CHF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of heart failure-related health behaviors.

Group Type: EXPERIMENTAL

Hospital-Community-Family-Care Management Platform Online

Intervention Type: OTHER

Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital

Subjects with CHF via conventional clinic visit according to the latest relevant guidelines

Intervention Type: OTHER

Subjects with CHF via conventional clinic visit according to the latest relevant guidelines

Subjects with CHF conventional clinic visit

Subjects with standardized treatment according to latest guidelines via conventional visit.

Group Type: ACTIVE_COMPARATOR

Subjects with CHF via conventional clinic visit according to the latest relevant guidelines

Intervention Type: OTHER

Subjects with CHF via conventional clinic visit according to the latest relevant guidelines

Interventions

Hospital-Community-Family-Care Management Platform Online

Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital

Intervention Type: OTHER

Subjects with CHF via conventional clinic visit according to the latest relevant guidelines

Subjects with CHF via conventional clinic visit according to the latest relevant guidelines

Intervention Type: OTHER

Other Intervention Names

Subjects with CHF follow-up

Eligibility Criteria

Inclusion Criteria

1. Male and female are aged 18 years old or over.

2. History of CHF for ≥3 months with NYHA functional class I-IV, of which class IV without strict bed rest.

3. Left ventricular ejection fraction (LVEF) ≤45% as assessed by echocardiogram. However, LVEF can be above 45% for patients with cardiac insufficiency caused by atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy and et al;

4. Treatment of CHF with stable and optimal pharmacological therapy according to Chinese guidelines for treatment of CHF. In general, optimal treatment will include a beta-blocker and an ACE inhibitor and/or an angiotensin receptor blocker, unless not tolerated. Medical therapy is defined as stable, if the subject has not started a new CHF drug class and the dose of drugs taken have not been changed during the 3 months prior to screening and randomization.

5. Ability to understand the requirements of the study and willingness to provide written informed consent (IC), and agreement to abide by the study restrictions and return for the required assessments.

6. Subjects are located in our coverage of the remote monitoring system.

Exclusion Criteria

1. Some secondary cardiomyopathy: hyperthyroid heart disease and anemic heart disease, and et al;

2. A history of malignancy, and life expectancy is less than 1 year；

3. Severe primary hepatic and renal insufficiency (alanine aminotransferase≥100 u/L, serum creatinine >3.0mg/dL, serum albumin <2.5g/L);

4. Refusal to participate;

5. Unable to visit outpatient clinics periodically;

6. Ambulatory population;

7. Patients were considered inappropriate to participate by researchers.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Science and Technology Department of Jiangsu Province

UNKNOWN

Sponsor Role: collaborator

Yangzhou Municipal Health Bureau

UNKNOWN

Sponsor Role: collaborator

Xiang Gu

OTHER

Sponsor Role: lead

Responsible Party

Xiang Gu

Professor of Cardiology, Director of Cardiovascular Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Xiang Gu, Docter

Role: PRINCIPAL_INVESTIGATOR

Department of cardiovascular medicine

Jianhua Shen, Docter

Role: PRINCIPAL_INVESTIGATOR

Department of cardiovascular medicine

Locations

Department of cardiovascular medicine,Northern Jiangsu Hospital

Yangzhou, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xiang Gu, Doctor

Role: CONTACT

sbyygx189@gmail.com

+86 0514 87373366

Facility Contacts

Jianhua Shen, Doctor

Role: primary

+86 0514 87373367

Other Identifiers

BL2013022

Identifier Type: -

Identifier Source: org_study_id